Avalon GloboCare Corp. is a clinical-stage biotechnology company, which engages in the development of immune effector cell therapy and laboratory services. The company is headquartered in Freehold, New Jersey and currently employs 2 full-time employees. The company went IPO on 2016-02-22. The firm operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The firm is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
ALBT stock price ended at $0.22 on 月曜日, after rising 15.79%
On the latest trading day Aug 10, 2026, the stock price of ALBT rose by 15.79%, climbing from $0.19 to $0.22. During the session, the stock saw a volatility of 21.05%, with prices oscillating between a daily low of $0.19 and a high of $0.23. Notably, trading volume dropped by 334.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 542.9K shares were traded, equating to a market value of approximately $2.6M.